Summary of Product Characteristics: Rowachol Capsules
Summary of Product Characteristics: Rowachol Capsules
Summary of Product Characteristics: Rowachol Capsules
Rowachol Capsules
Each capsule also contains Sodium Ethyl Parahydroxybenzoate and Sodium Propyl
Parahydroxybenzoate.
3 PHARMACEUTICAL FORM
4 CLINICAL PARTICULARS
Adults: The usual dosage is 1 to 2 capsules three times daily before meals.
Children aged 6 to 14 years: The usual dosage is 1 capsule twice daily before meals.
4.3 Contraindications
Known hypersensitivity to any of the active ingredients or to any of the inactive ingredients in
the formulation.
The product should only be used with caution in patients on anti-coagulants or drugs
dependent on the liver for metabolism and excretion.
The following ingredients of Rowachol capsules may cause allergic reactions: Sodium Ethyl
Parahydroxybenzoate (E215), Sodium Propyl Parahydroxybenzoate (E217) (possibly
delayed).
4.5 Interaction with other medicinal products and other forms of interaction
Rowachol Capsules should only be used with caution in patients on anti-coagulants or drugs
dependent on the liver for metabolism and excretion.
In rare cases, symptoms of belching and mint taste in the mouth have been reported, after
meals. These symptoms can be reduced by taking medication on an empty stomach 30
minutes before a meal.
A small number of patients reported appearance of pain and ulcers in the mouth. This
phenomenon is reversible and disappeared soon after stopping treatment.
4.9 Overdose
5 PHARMACOLOGICAL PROPERTIES
The several ingredients are well absorbed, metabolised in the liver and excreted in bile and
urine.
Not applicable.
6.2 Incompatibilities
Not applicable.
5 years.
Rowachol Capsules are packed in white, polypropylene tablet containers with polyethylene
matt white circular caps. The caps have 'tear-strips' fully attached all around and a 'pull-off
lip' above the 'tear-strip'.
Rowachol Capsules are available in tablet containers of 50 and 100 capsules. Not all pack
No special requirements.
7. LICENSE HOLDER
8. MANUFACTURER
The format of this leaflet was determined by the ministry of health and its content was checked
and approved in January 2016.